CSPIA
RNAM

Cary Street Partners Investment Advisory’s Avidity Biosciences RNAM Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$638 – 1559
2023
Q3 		$638 Hold
100
– – ﹤0.01% 1780
2023
Q2 		$1.11K Hold
100
– – ﹤0.01% 1640
2023
Q1 		$1.53K Hold
100
– – ﹤0.01% 1530
2022
Q4 		$2.22K Buy
+100
New +$1.49K ﹤0.01% 1499

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Cary Street Partners Investment Advisory's RNAM Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 100 shares — an estimated $638 sold.

Cary Street Partners Investment Advisory first reported a position in RNAM in Q4 2022 and held it in 4 quarters. The position peaked at $2.22K in Q4 2022. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 100 Avidity Biosciences shares in Q4 2023, an estimated $638.
  • Cary Street Partners Investment Advisory first reported a position in Avidity Biosciences in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Avidity Biosciences position peaked at $2.22K in Q4 2022.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.